Document is current

Article History

Received: 14 November 2024

Accepted: 21 March 2025

First Online: 21 April 2025

Declarations

:

: Koshiro Sonomoto has received speaking fees from AbbVie, Eli Lilly Japan, Gilead Sciences, GlaxoSmithKline, Janssen, Pfizer Japan, UCB Japan, Astellas, Ayumi, Chugai, Taisho, Tanabe Mitsubishi and has received research funding from UCB Japan. Shingo Nakayamada has received consulting fees, speaking fees, lecture fees, and/or honoraria from AstraZeneca, GlaxoSmithKline, Pfizer, Bristol-Myers, Astellas, Asahi-kasei, AbbVie, Chugai, Sanofi, Eisai, Gilead Sciences, Mitsubishi-Tanabe, Janssen, Eli Lilly, and Ayumi. Yoshiya Tanaka has received speaking fees and/or honoraria from Eli Lilly, AstraZeneca, AbbVie, Gilead, Chugai, Behringer-Ingelheim, GlaxoSmithKline, Eisai, Taisho, Bristol-Myers, Pfizer, Taiho, received research grants from Mitsubishi-Tanabe, Eisai, Chugai, Taisho. Yoshiya Tanaka is an Editorial Board member of Rheumatology and Therapy. Yoshiya Tanaka was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Hiroaki Tanaka and Atsushi Nagayasu have nothing to disclose.

: This study followed the Declaration of Helsinki and was approved by the Ethics Committee of the University of Occupational and Environmental Health School of Medicine (#UOEHCRB21-068). Informed consent was obtained from all participants based on the Ethical Guidelines for Medical and Health Research Involving Human Subjects issued by the Japanese Ministry of Health, Labor and Welfare. Written informed consent was obtained from participants enrolled after April 2015, and written or verbal consent was obtained from others.